Table 1A Baseline patients’ characteristics
All n = 922 | Immunocompromised patients n = 641 | Non-immunocompromised control (NICs) n = 281 | p-value | |
|---|---|---|---|---|
Age, Year, median [IQR] | 58.5 [40.0–72.0] | 66.0 [51.0–76.0] | 40.0 [32.0–54.0] | < 0.001 |
Sex, n (%) | < 0.001 | |||
Male | 439 (48%) | 360 (56%) | 79 (28%) | |
Female | 483 (52%) | 281 (44%) | 202 (72%) | |
Lineage– n(%) | < 0.001 | |||
B.1 | 12 (1.3%) | 7 (1.1%) | 5 (1.8%) | - |
Alpha | 18 (2.0%) | 11 (1.7%) | 7 (2.5%) | - |
Delta | 101 (11.0%) | 41 (6.4%) | 60 (21.4%) | < 0.001* |
Omicron BA.1 | 228 (24.7%) | 185 (28.9%) | 43 (15.3%) | < 0.001* |
Omicron BA.2 | 203 (22.0%) | 104 (16.2%) | 99 (35.2%) | < 0.001* |
Omicron BA.4/5 | 135 (14.6%) | 109 (17.0%) | 26 (9.3%) | 0.003* |
BQ.1 | 122 (13.2%) | 99 (15.4%) | 23 (8.2%) | 0.004* |
XBB | 103 (11.2%) | 85 (13.3%) | 18 (6.4%) | 0.003* |
Viral loads, Ct value, median [IQR] | 20.6 [18.0–23.0] | 19.6 [17.1–22.4] | 0.01 |